Creative biolabs is a leader in antibody-drug conjugate (ADC) development and we have established a comprehensive analytical platform to ensure high-quality and high-accuracy biochemical and in vitro efficacy characterization of a customized ADC. We offer a customarily tailored analysis package to evaluate the binding affinity of an ADC towards its designated target antigen and Fc receptors using various approaches including surface plasmon resonance (SPR), enzyme-linked immunosorbent assay (ELISA), and fluorescence-activated cell sorting (FACS) flow cytometry assay.